United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer/BioNTech to produce 4 billion Comirnaty doses in 2022, with 1.7 billion doses contracted by mid-October 2021 to generate ~$29 billion revenue. What will total Comirnaty revenue be in 2022?

Pfizer's One-Two-Punch Against COVID

BioNTech SE

Moderna

The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) COVID-19 vaccine shots. The new contracts with Pfizer/BioNTech and Moderna were accelerated in light of the emergence of the new Omicron variant.

Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses

3 Hard Facts Moderna and Pfizer Investors Need to Know About the Omicron Variant

Pfizer Inc's (PFE) Management Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)

Johnson & Johnson

Merck

Novavax

Vir Biotechnology

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

5 Biotech Stocks For Your December 2021 Watchlist

This red-hot pharma is far from hitting a peak.

3 Reasons Pfizer Stock Will Crush the Broader Market in 2022

Its big moment may be only a few weeks away.

Is This Latecomer a Better Buy Than Moderna and Pfizer?

Exact Sciences

The end of a co-promotion deal with Pfizer could work out well for Exact Sciences.

Exact Sciences Breaks Up With Pfizer -- Time to Buy?

Pfizer's CEO, Albert Bourla, believes that the vaccine currently in use for the COVID pandemic should still work with the new Omicron variant, but that it might have less protection. Bourla went on to add that the company would be able to produce a new vaccine within 100 days should it prove necessary, and that [.

Pfizer Vaccine Should Work Against Omicron, Just Less Efficiently

But not all coronavirus stocks were on the rise.

Why Novavax and Pfizer Are Trouncing the Market Today

The emergence of a worrisome coronavirus variant is benefiting shares of vaccine makers Moderna Inc, BioNTech and Pfizer as investors search for winning bets in markets roiled by uncertainty in recent days.

Analysis: As Omicron plays havoc with markets, shares of vaccine makers surge

Pfizer's chief scientist Mikael Dolsten highlighted two elements that will determine how the Omicron variant shapes the future of the pandemic.

Pfizer's top scientist Mikael Dolsten tells us the 2 factors that will determine if Omicron is a true threat and shares Pfizer's worst-case-scenario plan

The stock price of Pfizer Inc. (NYSE: PFE) increased by over 3% during intraday trading today. This is why it happened.

Pfizer (PFE) Stock: Why The Price Increased Today

Pfizer expects Comirnaty to account for $36B in revenue in FY21 and $29B in sales in FY22. Pfizer recently filed for the Emergency Use Authorization for its COVID-19 antiviral candidate, PAXLOVID, which is expected to bring in $24B in sales in FY22.

Novavax Vs. Pfizer Stock: Which Is The Better Buy?

"I'm very very confident that this drug works for all known mutations, including the Omicron one," Bourla told CNBC's Squawk Box.

Pfizer CEO is 'very confident' the company's oral COVID-19 pill will be effective against the new variant

WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with palbociclib, a CDK4/6 inhibitor, and sasanlimab, a su

NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

Pfizer continues to build upon its position as the undisputed leader in the mission to combat COVID-19.

Is This Leading COVID Stock a Buy Right Now?

Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal cancer screening test to health care providers. The decision follows an amendment to a co-promotion agreement signed by the two companies.

Pfizer Will Not Co-Promote Exact Sciences Colorectal Cancer Screening Test

The FDA could authorize COVID-19 boosters from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for use in 16 and 17-year olds as soon as next week, reports Wall Street Journal, citing a person familiar with the planning. The agency is planning to rapidly take action on a request by the companies to authorize boosters for 16 and 17 year-olds.

FDA May Authorize Pfizer-BioNTech COVID-19 Booster Shots For Age 16-17 Next Week: WSJ

The report comes as public experts track the coronavirus' new omicron variant.

Pfizer Reportedly Plans To Ask For Approval Of Covid Boosters For 16- And 17-Year-Olds

American Electric Power Company

Aflac

Cummins

Realty Income Corp

STORE Capital

Viatris

Vanguard High Dividend Yield ETF

The stock market, specifically the S&P 500, still is high, but is down for the month of November so far.

Dividend Stock Watch List: Lanny's December 2021 Edition

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

Amplify Travel Tech ETF

VanEck Vectors Biotech ETF

Amplify Video Game Tech ETF

iShares U.S. Pharmaceuticals ETF

United States Oil Fund LP

Direxion Work From Home ETF

Technology Select Sector SPDR Fund

The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.

ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus

The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

Adagio Therapeutics

The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a handful of biopharma stocks, according to a Morgan Stanley analyst.

News for Pfizer Stock (PFE)